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Abstract Hepatitis B is a DNA virus affecting hundreds of
millions of individuals worldwide. As the clinical sequelae
of cirrhosis and hepatocellular cancer are increasingly
recognized to be related to viral levels, the impetus
increases to offer treatment to those previously not treated.
With the development of more robust antivirals with
reasonable safety profiles, long-term treatment is becoming
more common. The oral nucleos(t)ide analogs have become
the preferred first-line therapies for most genotypes of
hepatitis B. Five are now available, all with different
potencies and resistance profiles. Long-term data spanning
several years are now available for most compounds in this
arena. This article focuses on the common natural variants
and those secondary to nucleos(t)ide therapy, as well as
diagnostic methods to detect resistance.
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Introduction
The hepatitis B virus (HBV) is a DNA virus of the
Hepadnaviridae family, similar to viruses that infect several
avian and mammalian species. Eight genotypes exist with
several subtypes defined by insertions or deletions of
nucleotides, but with less than 10% overall variation among
them [1]. Many viral genomic variants occur in nature, and
many more occur under the pressure of therapy, namely
direct-acting antivirals. Given the nature of the HBV
genome, variants produced under selection pressure are
archived indefinitely, which allows for a broadening of the
quasispecies pool and subsequent cross-resistance to other
drugs of similar structure. This article discusses the
mechanisms of HBV viral resistance and the clinical
implications.
Hepatitis B Virology
The HBV genome is comprised of two linear DNA strands
that partially overlap and are thus partially double stranded,
circular, and relaxed in configuration (rcDNA). The overall
length is 3200 nucleotides with the DNA polymerase bound
at the minus strand open 5′ end. There are four open
reading frames (ORFs; Pre-S/S, Pre-C/C, Pol, and X),
which overlap and are responsible for the synthesis of
several sets of proteins [2].
The replication of HBV is partially understood. The
virus binds to the hepatocyte via a surface protein and
enters the cell most likely through an endosome, although a
definitive receptor has not been elucidated in human HBV
[3]. Following viral entry into the cell, the HBV genome is
delivered to the nucleus of the cell and forms a covalently
closed circular (ccc DNA) configuration, which then acts as
a transcription template for viral RNAs. Conversion of the
rcDNA occurs via removal of the viral reverse transcriptase
from the 5′ end of the minus strand, and removal of a short
RNA segment from the 5′ end of the positive strand. These
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DOI 10.1007/s11894-009-0088-1viral RNA gene segments are the two surface mRNAs,
precore and pregenomic RNAs, and an X mRNA. The
pregenomic messenger RNA (mRNA) leads to synthesis of
the nucleocapsid unit and the viral reverse transcriptase,
which attaches to the 5′ end of its own mRNA template,
allowing for DNA synthesis. The cccDNA genome is
produced intracellularly and remains throughout the life of
the chronically infected host, allowing for viral genomic
replication for decades after the initial infection.
Several major protein products are produced by HBV.
The polymerase is necessary for viral replication, whereas
the core gene encodes the capsid protein, or hepatitis B core
antigen (HBcAg). The surface proteins are required for the
shell of the virus, and the X gene product is required for in
vivo infection in woodchucks; its role in human HBV is
less clear, although most researchers focus on its potential
carcinogenicity role [4, 5].
Naturally Occurring Mutations
Viral replication is estimated to be 10
11 virions per day,
with an error rate of 10
−5 [6]. Both precore and core
mutations are common, particularly in some geographic
regions, and are associated with some genotypes more
than others [7•]. The precore is a transition mutation, most
commonly in the 1896 codon position (G1896A) and
leads to a stop codon, resulting in decreased hepatitis B
early antigen (HBeAg) production. Genotypes A and F
rarely have precore mutations. The corresponding nucle-
otide of the stem-loop structure to position 1896 is
position 1858, which is a cytidine in these genotypes,
and the preferred pairing of cytidine is with a guanine at
position 1896. Conversely, in genotypes where precore
mutations are common, the 1858 position is often a
thymidine, which is more stable when paired with
adenine, hence the frequency of the precore mutation in
g e n o t y p e sB ,C ,a n dD[ 6].
Transcription of the precore and pregenomic RNAs is
controlled by the basal core promoter (BCP). Two
mutations described in this gene segment (A1762T,
G1764A) are associated with decreased HBeAg production.
Because of its location in the X ORF, two associated codon
mutations of the X protein can also occur (L130M, V1311);
however, binding of the hepatocyte transcription factor,
HNF-1, can lead to pregenomic RNA transcription and
production of HBeAg, even in the absence of wild-type
HBV [8]. This sometimes leads to the presence of both
HBeAg and hepatitis B early antibody (HBeAb) in the
same patient.
Independent of viral load, mutations occurring naturally
in the HBV genome lead to variable risks for hepatocellular
carcinoma (HCC). In a retrospective review of 2762 Asian
patients with largely HBeAg-negative disease, a
multivariable-adjusted HR of developing HCC was 1.76
(95% CI , 1.19–2.61) for genotype C versus genotype B
and 1.73 (95% CI, 1.13–2.67) for BCP A1762T/G1764A
versus wild type. Risk was highest among participants
infected with genotype C HBV, wild type for the precore
1896 variant and mutant for the BCP 1762/1764 variant
(adjusted HR=2.99; 95% CI, 1.57–5.70, P<0.001) [9].
The surface ORF encodes for three proteins, S (small),
M (middle), and L (large). Of these, S is the major surface
protein and is also part of the M and L components. It has
both a hydrophobic and hydrophilic region, the latter being
exposed on the surface of virions and subviral particles.
This segment includes the highly conserved a determinant,
which is recognized by protective antibodies. Flanked by
subdeterminants d or y, and w or r, and associated with
polymorphisms at amino acid positions 122 and 160, it
defines the four major serologic subtypes that have
associations with specific HBV genotypes. Point mutations
in this a determinant lead to escape mutants from
neutralizing antibodies. This finding is well described in
transplant recipients receiving HBIG [10].
Mechanisms of Antiviral Drug Resistance
As described above, the HBV genome is susceptible to
naturally occurring variants, most of which do not have
adequate replication fitness to be detectable with standard
commercially available assays. The high frequency of
variants is in large part because of the lack of proofreading
during reverse transcriptase, and the large replication space
available in the liver to allow for the existence of a broad
range of quasispecies. The apparent inefficiency of the
virus in replication, however, also allows it to overcome
immune pressure of the host, and hence it can escape
immune suppression. The mechanism is most notable in the
precore mutation, which reactivates years or decades after
natural suppression of the wild-type HBeAg-positive virus
by the host.
Hence, it is not surprising that pharmacologic pressure
leads to selection of these natural variants as the wild-type
virus is suppressed. The pharmacologic agent itself also
determines the likelihood of drug resistance based on its
potency and genetic barrier to mutations. Finally, other
factors such as host compliance, adequate dosing, and drug
metabolism will affect the rate of resistance.
Terminology of Drug Resistance
The definition of resistance is not as apparent as one might
assume. The inability to suppress virus by more than 10-
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proper dosing is not considered resistance, but rather
primary antiviral failure or nonresponse. Virus that is
suppressed, but increases by more than 10-fold above nadir
on two consecutive samples at least 1 month apart, is
considered secondary treatment failure. This outcome can
be the result of noncompliance, or most commonly
resistance [11].
Other commonly used terms are genotypic mutations or
polymorphisms, genotypic resistance, and phenotypic resis-
tance. A genotypic mutation or polymorphism is an amino
acid change not associated with antiviral resistance in vitro.
Genetic resistance refers to viral populations with amino
acid changes in the polymerase region that are associated
with some degree of phenotypic resistance to an antiviral
agent. Phenotypic resistance is determined by in vitro
assessment of drug resistance to viral populations, and can
often be quantified. Cross-resistance is a term indicating
that drugs of a similar class will have similar resistance
characteristics, which can be confirmed by phenotypic
assays. Mutations can be archived as cccDNA and persist
indefinitely, and can be passed on to others [12].
Genotypic and Phenotypic Resistance to HBV
Nucleos(t)ide Analogs
The mainstays of therapy for HBV are oral nucleos(t)ide
analogs (NA). Most of these were developed as a result
of HIV research. Indeed, the HIV polymerase is also an
RNA-dependent DNA polymerase, which is inhibited by
nucleoside agents. Nucleosides and nucleotides (addi-
tional phosphate group) have three structural categories:
L-nucleoside analogs such as lamivudine (LVD), emtri-
citabine (FTC), and telbivudine (LdT); acyclic phospho-
nates such as adefovir (ADV) and tenofovir (TDF); and
deoxyguanosine analogs such as entecavir. Figure 1
summarizes the frequency of mutations over several years
of clinical trials.
Resistance to NAs was noted with LVD, the first HIV/
HBV crossover compound. The polymerase gene of HBV
is 344 amino acids in length and has conserved domains
lettered A to F. There are eight codons in the polymerase of
HBV that are associated with primary drug resistance
(codons 169, 180, 181, 184, 202, 204, 236, and 250)
(Table 1).
Resistance to LVD was noted in the C domain
(rtM204V/I), and was initially referred to as the YMDD
motif mutation. A second compensatory mutation in the
upstream B domain is often present as well (rtL180M), and
improves replication of the variant. Other compensatory
mutations are also described that allow for improved
replication fitness, in particular the rtV173L mutation,
which accompanies rtL180M and rtM204V in about 10%
of cases with LVD use [13•]. The reported annual incidence
of resistance to LVD is as high as 32% [14]. However,
perhaps the best trial in recent years using LVD as the
control arm was the 1367-patient Globe trial assessing LdT.
In this 2-year study, the rate of LVD resistance in the
HBeAg-positive cohort was 39.5% versus 25.1% for LdT,
Fig. 1 Genotypic resistance
through 5 years for HBV
nucleoside analogs in
treatment-naïve patients
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10.8%. It must be noted that these resistance figures could
be predicted by the week-24 antiviral response. In patients
who had complete viral suppression by week 24, the
resistance in the LVD arm was only 10%, whereas it was
about 5% in the LdT group by week 104 [15]. This finding
clearly suggests that resistance rates can be decreased if
patients who are not responding to the drug are discon-
tinued early. A rollover study for an additional 2 years of
LdT was conducted on patients who were viral negative at
entry. Although viral suppression was relatively good for
those who remained in the study, 11.3% and 8% developed
resistance at years 3 and 4, respectively, in spite of being
viral-negative at study entry [16].
Entecavir (ETV) is an analog of d′-deoxyguanosine and
inhibits both negative-and positive-strand DNA synthesis.
In spite of its robust antiviral activity, mutations have been
described in two patterns, both of which involve the
rtM204V and the rtL180M. These mutation clusters are
rtI169T+rtL180M+rtM204V+rtM250V and rtL180M+
rtT184G+rtS202I and rtM204V. Because so many muta-
tions are required to lead to viral breakthrough, it is rare for
treatment-naïve patients to develop resistance to ETV. The
cumulative probability of resistance in HBeAg-positive and
HBeAg-negative patients is 1.2% at years 5 and 6 [17, 18].
The study design precluded continuation of drug in those
with high viral loads at the end of years 1 and 2, the group
most likely to develop resistance. This differs from earlier
trial designs using other compounds, but is more reflective
of clinical practice, in which drugs that are not working are
not continued as monotherapy. Conversely, in patients with
preexisting LVD mutations, the cumulative 6-year resis-
tance to ETV is 57% [18]. Given the high rate of resistance
in this group, most clinicians do not use ETV in LVD-
experienced patients.
Resistance to ADV occurs primarily in the B and D
domains of the polymerase, hence there is no cross-
resistance with compounds exhibiting C domain mutations.
The primary mutation in the D domain is the rtN236T
mutation, which may also harbor other mutations such as
rtP237H, rtN238T/D, rtV84M, and rtS85A, all of which
can occur independently but are both less common and
problematic [19]. The domain B rtA181V mutation leads to
a fourfold decrease in sensitivity to ADV, and in cases of
viral breakthrough is usually found in conjunction with the
rtN236T mutation. In a 5-year study of HBeAg-negative
patients, genotypic resistance to ADV monotherapy went
from 3% at year 2 up to 29% at year 5 [20]. In the original
HBeAg-positive study, because of errors in methodology, a
clear picture of resistance could not be determined, but was
reported as 20% at week 235 [21]. As with LdT and LVD,
patients with robust viral suppression by week 48 in the
case of ADV had less than 10% resistance by week 192 of
therapy, compared with nearly 50% in those not suppressed
by week 48 [20].
The other acyclic phosphonate compound is TDF, which
hascompleted3yearsofanintended8-yearprospectivestudy.
The first year compared TDF with ADV and found that no
resistance occurred in either arm. The ADVarm was changed
to open-label TDF at the beginning of year 2, and all patients
are to continue for an additional 7 years on TDF. The 3-year
data were presented at an international congress, and no
resistanceorsignature mutations toTDFhavebeendescribed.
An early report of rtA194T in the B–C domain border
suggested possible increase in IC50 when found with the
rtL180M and rtM204V mutations. However, this suggestion
has not been borne out in clinical studies. In the pivotal
study, patients who do not have complete viral suppression
can be changed to combination TDF and FTC (emtricitabine,
200 mg) at the discretion of the investigator. Of the 51
patients in both the HBeAg-positive and HBeAg-negative
studies, 34 had FTC added, and 17 remained on mono-
therapy. No difference was seen in viral kinetics up to week
144 after that point whether the patient was on combination
Antiviral Domain of polymerase gene (rt)
AB C D E
Lamivudine L80I V173L M204V/I
L180M
A181T/V
Telbivudine L180M M204I
A181T/V M204V (when combined
with L180M)
Entecavir L180M M204V/I M250V/I
T184S/A/I/L/C/G/M S202C/G/I
I169T
Adefovir A181T/V N236T
Tenofovir No signature mutations confirmed through week 144 of therapy
Table 1 HBV polymerase
domains and the resistant muta-
tions associated with
nucleos(t)ide analogs
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majority of patients had complete suppression [22, 23].
Entering the third year of therapy, 22 of 556 patients in
both studies were viremic with more than 400 copies/mL.
Of these 22 patients, 11 were on monotherapy with TDF
and 11 were on combination TDF and FTC. Genotypic
testing was done using population di-deoxy sequencing of
the HBV pol/RT. Conserved site changes were noted in a
total of five patients, usually at a single site, and included
rtR51K, rtL180M, rtM204V, rtA181T, rtR192H, rtG152E,
rtN236T, and rtR274Q. None of the conserved changes
were associated with persistent viral breakthrough; none
showed altered susceptibility to TDF in vitro using HepG2
cells transiently transfected with a pool of recombinant
HBV plasmid DNA or mutant virus created by site-directed
mutagenesis in the pCMV/HBV (genotype D) or pHY92
(genotype A) backbone. The addition of FTC did not
change the viral kinetics, nor did it appear to affect
conserved site changes [24].
Diagnosis of Resistance
Resistance testing is still an evolving practice and still not
done consistently outside research settings. Many clinicians
monitor biochemical parameters that indicate a histologic
flare of disease. An increasing number of clinicians are now
monitoring HBV DNA levels using polymerase chain
reaction (PCR) technology. This technology is a more
sensitive test to determine NA failure because biochemical
breakthrough may lag behind by months, or may not occur
at all. However, a rise in DNA or failure of DNA to drop or
continue to decline after initial response (plateau) is not
necessarily caused by resistance or NA failure. Patient
compliance is a critical component to successful therapy
and must be assessed. Additionally, some patients will have
suboptimal response to a given drug as a result of
pharmacogenomic parameters (eg, host polymorphisms)
that lead to inefficient drug metabolism.
To determine resistance, ideally specific genotyping of
the polymerase nucleotide sequence should be obtained at
baseline and at the time of virologic breakthrough during
treatment. Because the baseline data are usually not
available for practical reasons, the previously described
and known mutations associated with that particular drug
can be determined via viral genotyping (Table 2).
Genotypic Resistance Testing
Direct DNA sequencing using population-based PCR is a
common method of genotyping, but the sequencing usually
has a sensitivity of about 20% of the total quasispecies
pool. Amplification of clones of PCR products is more
Table 2 Genotypic and phenotypic assays
Advantages Disadvantages
Genotypic assays
Direct PCR sequencing Thorough identification of all mutations Poor sensitivity (∼ 20%)
Restriction fragment-length polymorphism Sensitive to∼5% Requires separate endonuclease reactions
for each mutation
Reverse hybridization line probe assay Sensitive Requires specific probe for every mutation
Commercially available
DNA microchip Able to detect new mutations Expensive
Not widely available
Mass spectrometric analysis Very sensitive Requires new primer for each mutation
Ultra-deep pyrosequencing Sensitive to 0.1% Early in development
Phenotypic assays
Transient transfection with site-specific
mutagenesis
Rapid Not applicable for multiple or complex
mutations Good for single mutations
Whole HBV genome amplification/cloning
and transfection
Whole HBV genome variability Requires cloning step
Cross-resistance testing
Cell transduction using Baculovirus vector High levels of replication Multiple vectors required
Cross-resistance testing
Permanent cell lines with expression of
HBV mutant genome
Reproducible New cell line needed for new mutations
Cross-resistance testing
HBV—hepatitis B virus; PCR—polymerase chain reaction
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cially available DNA sequencing assay is the TRUGENE™
HBV Genotyping Kit (TRUGENE HBV; Bayer HealthCare
LLC, Tarrytown, NY). A more sensitive direct-sequencing
method is restriction fragment-length polymorphism
(RFLP) analysis, which is sensitive to 5% of the total viral
pool, but requires a separate set of endonuclease reactions
for each mutant [25, 26••].
The hybridization-based technologies include real-time
PCR, sequencing with microchips using oligonucleotide
microarrays to improve sensitivity down to 10%, and the
most sensitive method within this group, matrix-assisted
laser-desorption ionization time of flight mass spectrom-
etry (MALDI-TOF MS) analysis of DNA fragments, which
is sensitive to 1% of the total viral pool. Hybridization is
limited by the need to have specific probes for every
mutant. The available commercial assay is the line-probe
assay (INNO-LiPA; Innogenetics, Ghent, Belgium), which
uses a series of short oligonucleotide probes to assess for
mutant sequences, with a sensitivity down to 5%. For most
clinical purposes, this option is very good [26••].
The newest and most powerful technology is ultra-deep
pyrosequencing (UDPS), which amplifies a DNA segment
and through the use of multiple primer pairs, sequences
single DNA strands via synthesis of complementary
strands. It has sensitivity of 0.1% and will find mutations
that have not been found with other less sensitive methods
[27•, 28]. This technology may become the standard in
clinical research arenas (Table 2).
Phenotypic Testing
The presence of genotypic mutations must be placed into
the clinical context of how this affects therapy. The use
of in vitro phenotypic analysis allows assessment of NA
susceptibility of a particular mutant clone. The compar-
ison is made to wild type and is reported as the effective
concentration of the NA required to inhibit 50% of the
v i r a lt a r g e t( E C 50). In general, a 10-fold change is
considered clinically meaningful, but changes higher than
that sometimes do not lead to drug failure in vivo, and
conversely, changes less than that occasionally impact
drug efficacy.
Most phenotyping methods involve the use of vectors.
Examples include an enzyme assay that uses polymerase
expressed in insect cells using a baculovirus vector,
transient transfection of recombinant HBV replication-
stable clones, and a recombinant HBV/Baculovirus in
hepatocyte cell lines. Permanent cell lines that express
mutant virus are a more reproducible method. However, as
new mutations are discovered, more cell lines need to be
produced [29] (Table 2).
Prevention and Management of Resistance
The first step in preventing resistance to NAs is to select
appropriate patients for treatment. Patients with a history of
noncompliance or those unable to remain on drug are more
likely to develop resistance through their actions. The
second step is to select a drug with a high barrier to
resistance and to monitor regularly to detect resistance
early.
Once the decision is made to start medication in a
given patient, the goal must be complete viral suppres-
sion, preferably within 1 year. In cases of viral load
plateau, an alternative drug or, rarely, a second drug may
be necessary. The use of combination NAs was inten-
sively studied when the available compounds were not
potent and had low barriers to resistance (LVD and
ADV). This strategy worked reasonably well and
decreased resistance and multidrug resistance [30].
However, with more potent single-agent compounds (eg,
ETV and TDF), there is little role for combination, except
in the setting of suboptimal response to one or the other.
The current American Association for the Study of Liver
Diseases guidelines on HBV has an algorithm for drug
resistance, which suggests the addition of a second drug if
resistance to LVD, LdT, or ADV is discovered [7•].
However, recent data suggest that monotherapy with
TDF may be sufficient for the commonly found mutations
associated with LVD, LdT, and ADV [22, 31]. Further
study is required to confirm these initial impressions. For
patients who develop either ETV resistance or, more
commonly, lack of complete response, the addition of
TDF in small series has been very successful [32]. Further
study is needed to determine if the combination is
necessary or if switching to TDF is adequate.
At this time, few indications exist to perform baseline
drug resistance testing before initiating therapy if the
patient is treatment-naïve. Currently available assays are
not sensitive enough and the results usually would not
alter management. However, once a patient is started on
treatment, careful assessment of DNA levels every
3 months is a must until viral negativity is achieved.
Using drugs with a high barrier to resistance is preferred,
and with these compounds most patients should achieve
undetectable levels within 1 year. For those still viremic
at week 48, but who continue to show viral decline,
continued therapy with a single agent is indicated. For
those who have a viral plateau, resistance testing is
suggested, along with assurance of patient compliance.
The addition of a second agent, or in some cases,
switching to another agent may be necessary to achieve
viral suppression. Once virus is undetectable, laboratory
monitoring of DNA can be performed every 6 months,
particularly for compliant patients on ETV or TDF. For
Curr Gastroenterol Rep (2010) 12:62–69 67patients who are treatment-experienced with a nucleoside
agent such as lamivudine, baseline monitoring may be
indicated, but because of the lack of sensitivity of most
assays, even existing mutations that are archived may not
be detected. On-treatment monitoring is imperative in
this group to detect existing mutations that emerge as
wild-type virus is suppressed. Medication adjustment can
be made accordingly in those cases.
Conclusions
Resistance to nucleoside agents targeting hepatitis B is an
important public health issue in terms of pharmacoeco-
nomics and the potential for multidrug-resistant HBV that
is passed to treatment-naïve individuals. Because the
current antiviral agents have only one target, it is logical
to restrict clinical use to only the most potent agents with
the lowest risk for resistance. For the oral agents, this is
tenofovir and entecavir. Both have reasonable safety
profiles and low resistance in treatment-naïve patients.
Ideally, new targets of drug therapy will allow for true
combination studies to maximize viral suppression and
inhibit the development of resistance. In lieu of this,
however, the responsible use of current single agents,
perhaps the use of two agents in selected settings, and
careful monitoring for compliance and viral breakthrough
are necessary to minimize viral resistance in HBV infection.
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